75. Cushing disease Clinical trials / Disease details

Clinical trials : 203 / Drugs : 191 - (DrugBank : 51) / Drug target genes : 62 - Drug target pathways : 128

34 trials found

diseases per page:

Showing 1 to 10 of 34 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04339751 (ClinicalTrials.gov)	March 24, 2022	8/4/2020	Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease	The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing's Disease	Cushing's Disease	Drug: Vorinostat	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Not yet recruiting	18 Years	N/A	All	22	Phase 2	United States
2	NCT04569591 (ClinicalTrials.gov)	March 24, 2022	29/9/2020	Corticotrophin-releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in ...	Corticotrophin-Releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in ...	Cushing's Disease;Pituitary Adenoma	Drug: Acthrel	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Not yet recruiting	8 Years	N/A	All	22	N/A	United States
3	EUCTR2019-004019-29-IT (EUCTR)	15/07/2021	07/10/2020	Italian study to evaluate the efficacy of retinoic acid and cabergoline therapy in combination in Cu ...	Medical combination therapy with retinoic acid and cabergoline in ACTH-secreting pituitary adenoma: ...	Cushing's disease in patients in whom pituitary surgery has not been curative or in situations where ...	Trade Name: Dostinex Product Name: Cabergolina Product Code: [G02CB03] INN or Proposed INN: CABERGOLINA ...	Dipartimento di Medicina-DIMED, università di Padova	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 2	Italy
4	NCT04844164 (ClinicalTrials.gov)	April 16, 2019	9/4/2021	Vitamin D Metabolism in Patients With Endocrine Disorders	Prospective Non-randomised Controlled Study of Vitamin D Metabolism in Patients With Endocrine Disor ...	Pituitary ACTH Hypersecretion;Acromegaly;Diabetes Mellitus, Type 1;Primary Hyperparathyroidism	Drug: Cholecalciferol 15000 UNT/ML Oral Solution	Endocrinology Research Centre, Moscow	Russian Science Foundation	Recruiting	18 Years	60 Years	All	240	Phase 1	Russian Federation
5	NCT03346954 (ClinicalTrials.gov)	December 11, 2017	15/11/2017	Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTHand Causing ...	Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTHand Causing ...	Cushing's Disease	Other: [11C]-Methionine PET/MRI	Hospices Civils de Lyon	NULL	Completed	18 Years	N/A	All	33	N/A	France
6	ChiCTR-OPC-17011664	2017-08-01	2017-06-14	A single center clinical study of EGFR/HER2 targeted inhibitor Lapatinib in the treatment of refract ...	A single center clinical study of EGFR/HER2 targeted inhibitor Lapatinib in the treatment of refract ...	Pituitary ACTH-secreting adenoma	Treatment group:lapatinib;	Peking Union Medical College Hospital	NULL	Pending	18	75	Both	Treatment group:30;		China
7	EUCTR2013-000267-84-PL (EUCTR)	05/02/2016	16/12/2015	Study to roll over patients who have completed a study with pasireotide and benefit from the study t ...	An open label, multicenter pasireotide roll over protocol for patients who have completed a previous ...	Cushing's diseaseAcromegalyNeuroendocrine tumorsPituitary tumorsEctopic ACTHsecreting (EAS) tumorsDu ...	Trade Name: Signifor Product Name: pasireotide Product Code: SOM230 INN or Proposed INN: pasireotide Oth ...	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 4	Portugal;United States;Taiwan;Greece;Thailand;Spain;Israel;Russian Federation;Italy;France;Mexico;Ca ...
8	NCT02468193 (ClinicalTrials.gov)	September 24, 2015	8/6/2015	Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome	A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Eff ...	Cushing's Syndrome;Ectopic Corticotropin Syndrome;Adrenal Adenoma;Adrenal Carcinoma;AIMAH;PPNAD	Drug: Osilodrostat	Novartis Pharmaceuticals	NULL	Completed	18 Years	85 Years	All	9	Phase 2	Japan
9	NCT02019706 (ClinicalTrials.gov)	February 12, 2014	21/12/2013	Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushi ...	Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushi ...	ACTH;Cushing's Syndrome	Radiation: DOTATATE PET-CT;Radiation: F-DOPA PET CT;Radiation: CT scan;Diagnostic Test: Routine MRI ...	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Recruiting	18 Years	80 Years	All	80	Phase 2	United States
10	EUCTR2013-002063-26-IT (EUCTR)	08/09/2013	23/07/2013	A trial with Metyrapone in Cushing's syndrome	A prospective open-label Phase 2 study of METYRAPONE as a preoperative treatment in patients with AC ...	Cushing's syndrome;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Trade Name: Matyrapone Product Name: Metyrapone Product Code: Metyrapone	S.C.D.U. MEDICINA INTERNA 1 Ospedale San Luigi Orbassano	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	15	Phase 2	Italy

First Previous1 2 3 4Next Last